Celgene’s Otezla® (Apremilast) receives European Marketing Authorisation
19 January 2015 | By Celgene
An oral therapy for moderate-to-severe chronic plaque psoriasis and active psoriatic arthritis, with no drug-specific pre-screening or laboratory monitoring requirements...